Using genomics to define pediatric blood cancers and inform practice (Q90029220)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

title

Using genomics to define pediatric blood cancers and inform practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

0 references

1

Rachel E Rau

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

author name string

Mignon L Loh

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

publication date

1 November 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

Hematology / the Education Program of the American Society of Hematology

10 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

volume

2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

page(s)

286-300

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

10 April 2020

cites work

1 reference

12 December 2020

Acute megakaryoblastic leukemia: experience of GIMEMA trials

1 reference

12 December 2020

Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study

1 reference

12 December 2020

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia

1 reference

12 December 2020

Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review

1 reference

12 December 2020

Origins of leukaemia in children with Down syndrome

1 reference

12 December 2020

AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity

1 reference

12 December 2020

Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.

1 reference

12 December 2020

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

1 reference

12 December 2020

Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner

1 reference

12 December 2020

Clinical implications of FLT3 mutations in pediatric AML.

1 reference

12 December 2020

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

1 reference

12 December 2020

The incidence and clinical significance of nucleophosmin mutations in childhood AML.

1 reference

12 December 2020

Discovery of the Philadelphia chromosome: a personal perspective

1 reference

12 December 2020

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

1 reference

12 December 2020

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

1 reference

12 December 2020

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

1 reference

12 December 2020

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

1 reference

12 December 2020

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

1 reference

12 December 2020

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

1 reference

12 December 2020

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro

1 reference

12 December 2020

Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

1 reference

12 December 2020

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute

1 reference

12 December 2020

Germline genomic variants associated with childhood acute lymphoblastic leukemia

1 reference

12 December 2020

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

1 reference

12 December 2020

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

1 reference

12 December 2020

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

1 reference

12 December 2020

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial

1 reference

12 December 2020

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

1 reference

12 December 2020

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

1 reference

12 December 2020

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome

1 reference

12 December 2020

CREBBP mutations in relapsed acute lymphoblastic leukaemia

1 reference

12 December 2020

Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group

1 reference

12 December 2020

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

1 reference

12 December 2020

NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern

1 reference

12 December 2020

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia

1 reference

12 December 2020

The role of mutations in epigenetic regulators in myeloid malignancies

1 reference

12 December 2020

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

1 reference

12 December 2020

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project

1 reference

12 December 2020

Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening

1 reference

12 December 2020

The genomic landscape of hypodiploid acute lymphoblastic leukemia

1 reference

12 December 2020

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

1 reference

12 December 2020

FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance

1 reference

12 December 2020

Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?

1 reference

12 December 2020

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

1 reference

12 December 2020

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

1 reference

12 December 2020

Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group

1 reference

12 December 2020

Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse

1 reference

12 December 2020

An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome

1 reference

12 December 2020

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

1 reference

12 December 2020

Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031

1 reference

12 December 2020

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

1 reference

12 December 2020

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

1 reference

12 December 2020

Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia

1 reference

12 December 2020

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003

1 reference

12 December 2020

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

1 reference

12 December 2020

Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.

1 reference

12 December 2020

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

1 reference

12 December 2020

A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults

1 reference

12 December 2020

Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia.

1 reference

12 December 2020

Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia

1 reference

12 December 2020

Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.

1 reference

12 December 2020

Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial

1 reference

12 December 2020

KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia

1 reference

12 December 2020

Genome-wide analysis links NFATC2 with asparaginase hypersensitivity

1 reference

12 December 2020

Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner

1 reference

12 December 2020

FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia

1 reference

12 December 2020

Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

1 reference

12 December 2020

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

1 reference

12 December 2020

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia

1 reference

12 December 2020

Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia.

1 reference

12 December 2020

The genomic landscape of juvenile myelomonocytic leukemia

1 reference

12 December 2020

Pediatric Cancer Genetics Research and an Evolving Preventive Ethics Approach for Return of Results after Death of the Subject

1 reference

12 December 2020

Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study

1 reference

12 December 2020

Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels

1 reference

12 December 2020

Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults

1 reference

12 December 2020

Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents

1 reference

12 December 2020

Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis

1 reference

12 December 2020

Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia

1 reference

12 December 2020

Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

1 reference

12 December 2020

MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study

1 reference

12 December 2020

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

1 reference

12 December 2020

Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study

1 reference

12 December 2020

Synergism of FAK and tyrosine kinase inhibition in Ph B-ALL.

1 reference

12 December 2020

Genomic Classification and Prognosis in Acute Myeloid Leukemia

1 reference

12 December 2020

Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia

1 reference

12 December 2020

Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing

1 reference

12 December 2020

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

1 reference

12 December 2020

Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.

1 reference

12 December 2020

Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups

1 reference

12 December 2020

Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.

1 reference

12 December 2020

1 reference

12 December 2020

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

1 reference

12 December 2020

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia

1 reference

12 December 2020

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

1 reference

12 December 2020

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.

1 reference

12 December 2020

NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group

1 reference

12 December 2020

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

1 reference

12 December 2020

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

1 reference

12 December 2020

Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.

1 reference

12 December 2020

Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome

1 reference

12 December 2020

Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene

1 reference

12 December 2020

Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes.

1 reference

12 December 2020

The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia

1 reference

12 December 2020

MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.

1 reference

12 December 2020

Multivalent Small-Molecule Pan-RAS Inhibitors.

1 reference

12 December 2020

Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.

1 reference

12 December 2020

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial

1 reference

12 December 2020

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial

1 reference

12 December 2020

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group

1 reference

12 December 2020

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

1 reference

12 December 2020

Midostaurin approved for FLT3-mutated AML.

1 reference

12 December 2020

Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions.

1 reference

12 December 2020

Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients

1 reference

12 December 2020

Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.

1 reference

12 December 2020

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.

1 reference

12 December 2020

Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient

1 reference

12 December 2020

Philadelphia chromosome-like acute lymphoblastic leukemia

1 reference

12 December 2020

Pharmacogenomics in acute lymphoblastic leukemia

1 reference

12 December 2020

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.

1 reference

12 December 2020

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.

1 reference

12 December 2020

TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children

1 reference

12 December 2020

Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia

1 reference

12 December 2020

Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis

1 reference

12 December 2020

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

1 reference

12 December 2020

Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.

1 reference

12 December 2020

RecurrentRARBTranslocations in Acute Promyelocytic Leukemia LackingRARATranslocation

1 reference

12 December 2020

10.1182/ASHEDUCATION-2018.1.286

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30504323 AND SRC:MED&resulttype=core&format=json

10 April 2020

PubMed publication ID

30504323

1 reference